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Hepatitis C virus (HCV) NS3 polymorphism Q80K is mainly found in patients with HCV genotype (G) 1a,
and has been associated with a reduced treatment response to simeprevir with pegylated interferon (P)
and ribavirin (R). Prevalence of Q80K among G1 patients may vary geographically. Q80K prevalence in the
North-American G1 population in a recent study was 34%.
We conducted a post hoc meta-analysis of Q80K polymorphism prevalence among HCV G1-infected
patients enrolled in simeprevir and telaprevir Phase II/III studies. Baseline HCV NS3/4A protease
sequences were analysed by population sequencing to determine Q80K prevalence.
Overall, of 3349 patients from 25 countries in the European region analysed, 35.8%, 63.8% and 0.3% of
patients had G1a, G1b and other/unknown HCV G1 subtypes, respectively. Q80K was detected at baseline
in 7.5% of HCV G1 patients overall. Examination by subtype showed that 19.8%, 0.5% and 18.2% of patients
with G1a, G1b and other/unknown HCV G1 subtypes had the Q80K polymorphism, respectively. Among
countries in the European region with sequencing data available for eitherP20 patients with G1a and/or
P40 G1 patients overall, the Q80K prevalence in G1 ranged from 0% in Bulgaria to 18.2% in the UK. Q80K
prevalence also varied within G1a across different countries.
HCV subtype 1a was correctly determined in 99% of patients by the LiPA v2 assay.
A low overall prevalence of Q80K was observed in HCV G1-infected patients in the European region,
compared with North America. However, the prevalence varied by country, due to differing ratios of
G1a/G1b and differing Q80K prevalence within the G1a populations.
 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
HCV NS3/4A protease inhibitors (PIs) are used as part of differ-
ent regimens to treat patients with chronic hepatitis C virus (HCV)
infection. Naturally occurring amino acid substitutions in the NS3
protease domain, also referred to as polymorphisms, have beenreported (Bartels et al., 2013; Gaudieri et al., 2009; Kuntzen
et al., 2008). These polymorphisms can reduce the antiviral activity
of PIs (Jacobson et al., 2014; Manns et al., 2014; De Meyer et al.,
2012; Barnard et al., 2013).
Simeprevir is an approved PI, indicated for use in combination
with other medicinal products for the treatment of chronic hepati-
tis C genotype (G) 1 and 4 infection in adult patients (Simeprevir
Summary of Product Characteristics). Phase III trials of simeprevir
in combination with pegylated interferon and ribavirin (PR) in HCV
G1- and G4-infected treatment-naïve and prior relapse patients
showed sustained virologic response after 12 weeks (SVR12) rates
of approximately 80% (Jacobson et al., 2014; Manns et al., 2014;
Forns et al., 2014; Moreno et al., 2014).
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confers low level resistance to in vitro simeprevir activity. G1a iso-
lates with a baseline Q80K polymorphism resulted in a median fold
change in simeprevir EC50 value of 11 in a transient replicon assay
(Verbinnen et al., 2014). It is the most common polymorphism
among the NS3 polymorphisms associated with reduced activity
of NS3/4A PIs (Bae et al., 2010).
The presence of Q80K at baseline has only a minor effect on ini-
tial response to treatment with simeprevir in combination with PR
but may facilitate the emergence of additional mutations and sub-
sequent failure to simeprevir/PR therapy (Lenz et al., 2014). Among
patients treated with simeprevir in combination with PR, SVR rates
were reduced in HCV G1 patients with Q80K compared with G1a
patients without this polymorphism. SVR12 was lower in patients
with Q80K than those without Q80K (58% versus 84% in HCV G1a
treatment-naïve patients and 47% versus 79% in G1a prior relaps-
ers) (Forns et al., 2014; Jacobson et al., 2013). In the same studies
G1b patients had SVR12 rates of 85% in HCV treatment-naïve and
86% in prior relapsers. Most other PIs do not appear to be affected
by Q80K. For example, both telaprevir (Shafran, 2014) and falda-
previr (Berger et al., 2014) have similar SVR rates with and without
Q80K polymorphism at baseline when combined with PR, while
the virologic response to asunaprevir was shown to be less robust
in patients with Q80K than patients without Q80K (McPhee et al.,
2012). However no data to show the effect of Q80K on SVR in
asunaprevir-containing regimens have been published. In parita-
previr, EC50 was increased 3-fold in K80 compared with Q80, but
no data is currently available for the effect of Q80K on SVR with
regimens containing this PI (Pilot-Matias et al., 2014). Structural
differences between PIs account for the different impacts of amino
acid substitutions, such as Q80K, on drug activity.
Alternative therapy to simeprevir plus PR should be considered
in HCV G1a patients who have detectable Q80K polymorphism at
baseline according to both the European Association for the Study
of the Liver (EASL recommendations) and the joint American Asso-
ciation for the Study of Liver Diseases (AASLD) and Infectious Dis-
eases Society of America (IDSA) recommendations (AASLD/IDSA
recommendations). However, recent results with simeprevir-con-
taining, interferon-free therapy showed that the effect of Q80K
on SVR12 rates seems to be substantially attenuated or possibly
eliminated (Lawitz et al., 2014). The COSMOS study, which evalu-
ated simeprevir combined with sofosbuvir with or without ribavi-
rin for 12 or 24 weeks, among HCV G1 prior-null responders with
METAVIR F0–4, and treatment-naïve patients with METAVIR F3–
4, showed SVR rates of 88% and 94% in G1a patients with and with-
out baseline Q80K, respectively, in the intent-to-treat (ITT) popula-
tion (Lawitz et al., 2014). Of the six patients (4%) who experienced
viral relapse in the COSMOS study, four had Q80K at baseline.
Recent interim real-life data of simeprevir in combination with sof-
osbuvir with or without ribavirin in American patients has shown
similar results to COSMOS with overall SVR4+ (SVR achieved four
weeks or more after end of treatment) of 89% (269/303) in HCV-
TARGET (Sulkowski et al., 2014a). This cohort notably has a high
proportion of difﬁcult-to-treat patients including 61% having HCV
G1a and 57% being cirrhotic (Sulkowski et al., 2014a). Similarly
in the US TRIO Health cohort, 82% (n = 276, intent to treat popula-
tion), of HCV G1 patients achieved SVR12 with the same regimen
(SVR12 was 90% in per protocol population, n = 252). Again, this
cohort was made up of difﬁcult-to-treat patients, and of those
selected for this regimen, 63% were infected with HCV G1a and
45% had cirrhosis (Dieterich et al., 2014). Data relating to the effect
of Q80K on efﬁcacy are not available in either HCV-TARGET or TRIO
cohorts as Q80K testing was rarely performed.
This study aimed to provide Q80K prevalence data across the
European region. The presented results inform physicians on their
local prevalence of HCV G1a versus 1b, together with the frequencyof Q80K in the overall G1 population, HCV G1a and other rare HCV
G1 subtype isolates. Additionally, the concordance of two com-
monly used HCV G1 subtyping assays (TRUGENE and Versant LiPA
v2) with a NS5B or NS3/4A sequence-based HCV genotype subtyp-
ing assay was determined.2. Materials and methods
Demographic and baseline data from patients in the European
region were pooled from 14 telaprevir and simeprevir Phase IIb
and III clinical studies. Studies of patients who were HCV treat-
ment-naïve were QUEST-1 (Jacobson et al., 2014), QUEST-2
(Manns et al., 2014), PILLAR (Fried et al., 2013), C208 (Marcellin
et al., 2011), OPTIMIZE (Buti et al., 2014), PROVE2 (Hézode et al.,
2009), ADVANCE (Jacobson et al., 2011), ILLUMINATE (Sherman
et al., 2011) and REPLACE (clinicaltrials.gov). Studies of patients
who had received prior HCV interferon-based treatment were
ASPIRE (Zeuzem et al., 2014), PROMISE (Forns et al., 2014), ATTAIN
(Reddy et al., 2014), REALIZE (Zeuzem et al., 2011) and PROVE3
(McHutchison et al., 2010). For each of the studies the ITT popula-
tion was analysed, deﬁned as all patients who received at least
one dose of study drug. Descriptive statistics on the prevalence of
Q80K across different subgroups were tabulated by HCV genotype
subtype. Population sequencing was performed as described previ-
ously (Koletzki et al., 2013). HCV genotype subtypes were deter-
mined at screening by TRUGENE or Versant LiPA v2 assay (both
Siemens Healthcare Diagnostics, IL, USA), depending on the study.
HCV genotype subtypes were also determined at baseline by
sequencing a 329 base pair region within NS5B, or by sequencing
the NS3/4A region, depending on the study, both followed by basic
local alignment search tool (BLAST) analysis. For the prevalence
analyses reported here, the HCV genotype subtypes determined
by the NS3/4A or NS5B region were used, and if not available, the
results from the LiPA v2 or TRUGENE assay were used instead.
The concordance of results of the TRUGENE and LiPA v2 HCV
genotype subtyping assays (which are commercially available)with
results from NS3/4A or NS5B sequence-based genotype subtyping
assays was also analysed. Only samples that had results available
with both the LiPA v2 and NS3/4A or NS5B sequence-based assays
or both the TRUGENEandNS3/4AorNS5B sequence-based genotype
subtyping assay were included in this analysis.3. Results
The ITT population of these studies included 3462 patients from
25 countries in the European region: Austria, Belgium, Bulgaria,
Czech Republic, Denmark, France, Germany, Greece, Hungary,
Ireland, Israel, Italy, the Netherlands, Norway, Poland, Portugal,
Romania, Russia, Slovakia, Spain, Sweden, Switzerland, Turkey,
Ukraine and the UK. Baseline NS3/4A population sequencing data
were available for 3349 (96.7%) patients and HCV genotype
subtype and Q80K prevalence data is reported for this subset.
Country-speciﬁc data are only shown for countries that had
sequencing data available for at least 20 G1a patients (Austria,
Belgium, France, Germany, Italy, the Netherlands, Norway, Poland,
Portugal, Spain, Sweden and the UK) or at least 40 G1 patients
overall (Bulgaria, Romania and Russia).
3.1. HCV genotype subtype and Q80K prevalence
Overall, 35.8% (1200/3349) of patients had G1a, 63.8% (2138/
3349) G1b and 0.3% (11/3349) had another or unknown G1 sub-
type. Of the 11 patients with another or unknown G1 subtype,
two were G1c, two were G1d, three were G1e, one was G1i and
one was G6e (this patient was determined to be G1b by TRUGENE
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unknown. For these two patients the NS5B sequence-based HCV
genotype subtype assay failed and only results from the TRUGENE
assay were available and are reported here.
The overall prevalence of Q80K was 7.5% (250/3349), broken
down as 19.8% (237/1200) in G1a, 0.5% (11/2138) in G1b and
18.2% (2/11) in other or unknown G1 subtypes (two patients with
HCV G1d; none of the other patients with other or unknown G1
subtype had Q80K). Overall prevalence of baseline Q80K among
G1-infected patients in countries with sequencing data for at least
20 G1a patients and/or at least 40 overall G1 patients ranged from
0% in Bulgaria to 18.2% in the UK (Fig. 1 and Table 1). Prevalence of
Q80K was higher when only considering the G1a population com-
pared with the overall population. In countries with sequencing
data for at least 20 G1a patients, Q80K prevalence in G1a patients
ranged from 4.8% in Norway to 75.0% in Poland.
HCV G1b prevalence also varied throughout the European
region, impacting on Q80K prevalence in the overall HCV G1 popu-
lation. When considering countries with sequencing data for at
least 40 G1 patients, Poland, Romania and Russia had high G1b
prevalences of 95.5%, (444/465), 100% (92/92) and 96.7% (177/
183), respectively, amongst the overall G1 population. These
resulted in low overall Q80K prevalences of 3.7% (17/465), 1.1%
(1/92) and 2.2% (4/183), respectively. While other countries, such
as Spain and Bulgaria, had a substantial proportion of HCV G1a of
31.2% (82/263) and 28.6% (14/49), respectively, but also had low
overall Q80K prevalence of 2.7% (7/263) and 0% (0/49), respectively,
due to low prevalence of Q80K among the G1a population (8.5% [7/
82] in Spain and 0% [0/14] in Bulgaria). In contrast, the UK, where
overall Q80K prevalence in the HCV G1 population amounted to
18.2%, had a low G1b prevalence of 19.7% (39/198) and a Q80K
prevalence within the G1a population of 22.6% (36/159).
No baseline demographics or disease characteristics analysed,
other than country or G1 subtype, appeared to be linked to Q80K
prevalence, (Supplementary Table). This included race, ethnicity,Fig. 1. Overall HCV genotype 1 prevaleIL28B genotype, METAVIR score, whether the patient was PR-ther-
apy experienced and, for patients who had prior PR therapy, the
response to treatment. (Supplementary Table).
3.2. HCV genotype subtype assay concordance
A total of 3368 patients had results available with both the LiPA
v2 and NS3/4A or NS5B sequence-based assays or both the TRU-
GENE and NS3/4A or NS5B sequence-based genotype subtyping
assay, and were included in this analysis.
In total, 1909 samples had results available with both LiPA v2
and NS3/4A or NS5B sequence-based assays (Table 2). Overall,
98.8% of samples (1887/1909 samples; 657 G1a and 1230 G1b)
had the same HCV genotype subtype with both the LiPA v2 and
the NS3/4A or NS5B sequence-based assays. Eleven patients
(0.6%) determined as HCV G1b by LiPA v2 were classiﬁed as G1a
by NS5B or NS3/4A sequence-based assay. Nine of these eleven
patients had Q80K data available. Of these nine patients 33.3%
(3/9) had Q80K. An additional three samples determined as HCV
G1b by LiPA v2 were classiﬁed as G1d, G1e and G1l with the
NS3/4A or NS5B sequence-based assays. Three samples determined
as G1a with LiPA v2 were classiﬁed as G1b with the NS3/4A or
NS5B sequence-based assay. For four patients the HCV G1 subtype
could not be determined via LiPA v2; three of these were G1a and
one G1b based on NS3/4A or NS5B genotype subtyping assays.
None of these patients had a Q80K polymorphism.
A total of 1461 samples had results available with both TRU-
GENE and NS3/4A or NS5B sequence-based assays (Table 3). Over-
all, 79.6% of samples (1163/1461 samples; 405 G1a, 756 G1b, one
G1c and one G1g) had the same HCV genotype subtype with both
assays. The TRUGENE assay identiﬁed 79 samples as HCV G1b that
were classiﬁed as either HCV G1a (74/79), unknown HCV G1 sub-
type (2/79), G1d (2/79) or G6e (1/79) by the NS3/4A or NS5B
sequence-based assay. Of the 74 patients determined as G1b with
TRUGENE but shown to be G1a by NS3/4A or NS5B sequence-basednce of Q80K by European country.
Table 1
Patients with a baseline Q80K polymorphism, by country (ITT population).
Other/unknown
All HCV G1 HCV G1a HCV G1b HCV G1
N n (%)a N n (%) N n (%) N n (%)a
[95% CI] [95% CI] [95% CI] [95% CI]
All countries 3349 1200 2138 11
Q80K 250 (7.5) 237 (19.8) 11 (0.5) 2 (18.2)
[6.6–8.4] [17.5–22.1] [0.3–0.9] [2.3–51.8]
Austria 204 109 94 1
Q80K 19 (9.3) 18 (16.5) 1 (1.1) 0
[5.7–14.2] [10.1–24.8] [0.0–5.8]
Belgium 211 61 147 3
Q80K 12 (5.7) 11 (18) 1 (0.7) 0
[3.0–9.7] [9.4–30.0] [0.0–3.7]
Bulgaria 49 14 35 0
Q80K 0 0 0 0
France 521 275 244 2
Q80K 41 (7.9) 38 (13.8) 3 (1.2) 0
[5.7–10.5] [10.0–18.5] [0.3–3.6]
Germany 587 241 345 1
Q80K 72 (12.3) 70 (29) 2 (0.6) 0
[9.7–15.2] [23.4–35.2] [0.1–2.1]
Italy 210 60 150 0
Q80K 13 (6.2) 12 (20) 1 (0.7) 0
[3.3–10.4] [10.8–32.3] [0.0–3.7]
Netherlands 41 26 14 1
Q80K 3 (7.3) 3 (11.5) 0 0
[1.5–19.9] [2.4–30.2]
Norway 26 21 5 0
Q80K 1 (3.8) 1 (4.8) 0 0
[0.1–19.6] [0.1–23.8]
Poland 465 20 444 1
Q80K 17 (3.7) 15 (75) 2 (0.5) 0
[2.1–5.8] [50.9–91.3] [0.1–1.6]
Portugal 46 37 9 0
Q80K 3 (6.5) 3 (8.1) 0 0
[1.4–17.9] [1.7–21.9]
Romania 92 0 92 0
Q80K 1 (1.1) 0 1 (1.1) 0
[0.0–5.9] [0.0–5.9]
Russia 183 6 177 0
Q80K 4 (2.2) 4 (66.7) 0 0
[0.6–5.5] [22.3–95.7]
Spain 263 82 181 0
Q80K 7 (2.7) 7 (8.5) 0 0
[1.1–5.4] [3.5–16.8]
Sweden 59 46 13 0
Q80K 7 (11.9) 7 (15.2) 0 0
[4.9–22.9] [6.3–28.9]
UK 198 159 39 0
Q80K 36 (18.2) 36 (22.6) 0 0
[13.1–24.3] [16.4–29.9]
CI: conﬁdence interval.
Data are shown per country for countries with at least 20 genotype 1a patients and/
or at least 40 genotype 1 patients overall.
HCV geno/subtype is based on the NS5B or NS3/4 assay, and if not available on LiPA
v2 or TRUGENE results.
a Includes one patient determined as genotype 1b and genotype 6e with TRU-
GENE and NS5B based assay, respectively.
Table 2
Cross-tabulation of HCV genotype subtype determined by NS3/4A or NS5B sequence-
based assay versus HCV genotype subtype determined by LiPA v2 (ITT population).
Table 3
Cross-tabulation of HCV genotype subtype determined by NS3/4A or NS5B sequence-
based assay versus HCV genotype subtype determined by TRUGENE (ITT population).
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tionally, 43 samples determined as G1a with the TRUGENE assay
were classiﬁed as G1b (37/43), other HCV genotype subtypes (5/
43) or unknown HCV G1 subtype (1/43) when tested with the
NS3/4A or NS5B sequence-based assay. In addition, of 176 samples
in which G1 subtype was not determined with the TRUGENE assay,
77 were G1a, 98 were G1b and one was G1d with the NS3/4A or
NS5B sequence-based assay.
4. Discussion
The prevalence analyses reported here, comprised a large data-
set of 3349 patients from 25 countries in the European region andshowed a low overall prevalence of Q80K (7.5%). This low Q80K
prevalence is due, in part, to the relatively high (63.8%) occurrence
of G1b and the lower Q80K prevalence in G1a patients in the Euro-
pean region. This is in contrast to previously reported data, which
generally included a high proportion of sequences from North
America, such as a reported Q80K prevalence of 47% (121/268) in
G1a (Bae et al., 2010).
Overall, G1 Q80K prevalence varied by country from 0% to
18.2%. In countries with a low prevalence (Romania, Russia and
Poland) this was driven by the very low percentage of G1a patients
in these countries. These data are consistent with previous reports
of high G1b prevalence in Romania of 93.5% (143/153) and Poland
97.1% (100/103) (Grigorescu, 2009; Chlabicz et al., 2008). Of note,
Norway and Portugal had the lowest HCV G1b prevalences but also
low Q80K prevalences due to a low Q80K prevalence within their
respective HCV G1a populations.
A recent analysis of Q80K in HCV G1 patients showed that Q80K
prevalence was higher in both the overall North American popula-
tion (34.4%) and in the North American G1a population (48.1%)
than in European patients overall (6.1%) and the European G1a
population (19.4%) (European data were a subset of the study pre-
sented here (Lenz et al., 2014)).
The prevalence of Q80K within HCV G1a patients also varied,
ranging from low prevalence in Norway, Spain and Portugal of
4.8%, 8.5% and 8.1%, respectively to higher prevalence of 75.0%,
29.0%, 22.6% in Poland, Germany and the UK, respectively. Despite
the very high Q80K prevalence in G1a patients in Poland, its overall
HCV G1 Q80K prevalence (3.7%) is comparable to Spain (2.7%) and
Portugal (6.5%) due to very low G1a prevalence. Other data on
Q80K prevalence by countries are limited and frequently based
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genotype 1a in France (14%) Italy (20%), Sweden (15%) and UK
(23%) in our study were similar with those previously reported in
French (7%), Italian (14%), Swedish (6%) and Scottish (16%) patients
(Berger et al., 2014) as well the more recent French cohort (11%
prevalence) (Morel et al., 2014). These data show that the ratio
of G1a to G1b is not the only factor that determines Q80K preva-
lence in HCV G1 overall, but also that the Q80K prevalence within
the HCV G1a population varies by country.
Different prevalences of G1a clades and the Q80K prevalence in
these clades may provide some explanation for Q80K being less
frequent in G1a-infected patients from Europe and the variation
of Q80K prevalence within the European region. Two distinct
clades of G1a (clade 1 and clade 2) have been identiﬁed by phylo-
genetic analysis (Pickett et al., 2011). A different distribution of
naturally occurring amino acid substitutions exist between clades.
The Q80K polymorphism is only found in clade 1 and not clade 2
(48.9% versus 0%; n = 293 sequences) (De Luca et al., 2013). The
Q80K polymorphism is believed to have originated in the US, with
96% of HCV infections in an international cohort of 677 patients
with Q80K present analysed descending from a single lineage orig-
inating in the 1940s (McCloskey et al., 2014). A higher prevalence
of HCV genotype 1a clade 1 (72.7%) was seen in the Los Alamos
database (which includes sequences mainly from the USA) than
in an equivalent Italian cohort (47.3%) (De Luca et al., 2013), and
in a French cohort (43.2%) (Morel et al., 2014) suggesting a differ-
ence in HCV G1a sequences between North American and Euro-
pean populations. It is likely that clade 2 originated in Europe
(De Luca et al., 2013).
Additional epidemiological studies are needed to further deter-
mine the prevalence of the two GT1a clades as well as of Q80K
across Europe but also to assess potential regional differences
which may be present within a speciﬁc country.
Baseline testing for Q80K is recommended in HCV G1a patients
before initiating treatment with simeprevir plus PR (Simeprevir
Summary of Product Characteristics). However, our data suggest
that Q80K baseline testing may not be cost-effective in certain
regions (e.g. Eastern Europe), although full cost-effectiveness stud-
ies would be needed to determine this. Another consideration
when assessing the need for Q80K testing is the use of on-treat-
ment stopping rules, which should be applied when initiating sim-
eprevir plus PR (Simeprevir Summary of Product Characteristics).
Patients with HCV RNA P25 IU/mL at Week 4 have a low chance
of achieving SVR; therefore, if a treatment response (i.e. HCV
RNA <25 IU/mL) to simeprevir is not reported at Week 4, all treat-
ment should be stopped and an alternative management plan
agreed upon. Conversely, patients with an early treatment
response have a high chance of achieving SVR, irrespective of base-
line predictive factors (including Q80K) (Jacobson et al., 2013;
Forns et al., 2014). Hence, determining early responses to simepre-
vir plus PR provides a useful tool for assessing the utility of this
treatment in individual patients, especially in the setting where
Q80K testing has not been performed. The effect of Q80K on SVR
is substantially attenuated or possibly eliminated when simeprevir
is taken with sofosbuvir with or without ribavirin (Lawitz et al.,
2014).
Alternative interferon-free therapies currently approved in HCV
G1 include sofosbuvir in combination with daclatasvir, and sof-
osbuvir in a ﬁxed dosed combination with ledipasvir. Both combi-
nations have shown to be effective in patients with mutations
associated with resistance to protease inhibitors (Sulkowski
et al., 2014b; Afdhal et al., 2014). Additionally, the drug combina-
tion of paritaprevir (boosted with ritonavir), dasabuvir and omb-
itasvir is expected to be approved soon with other therapies in
clinical development. It is unlikely that there will be one regimen
that will be suitable for all patients due to the range of baselinecharacteristics, the genetic differences between genotypes and
the naturally occurring polymorphisms that can infer resistance
to various drugs.
Since population sequencing rarely fails to detect the Q80K
polymorphism when it is present, this eliminates the need for
more sensitive deep sequencing technologies. In a subset of
patients (n = 274) from pooled Phase II and III simeprevir studies,
70 patients (26%) had Q80K polymorphism detected by population
sequencing, and only two additional patients (0.7%) having Q80K
detected by deep sequencing (Fevery et al., 2014). Similarly in a
telaprevir study, out of 185 samples that had no Q80K detected
at baseline by population sequencing, only one had Q80K detected
by deep sequencing (Dierynck et al., 2014). The clinical relevance
of such minority species harbouring Q80K is unknown.
Given that Q80K testing is only recommended in HCV G1a
patients when considering treatment with simeprevir and PR, this
dataset was also used to determine the consistency of the commer-
cially available LiPA v2 and TRUGENE assays compared with NS3/
4A or NS5B sequence-based genotype subtyping assays, which
are considered the most accurate methods for standard HCV geno-
type subtyping. The LiPA v2 assay had very high concordance
(98.8%) with NS3/4A or NS5B assays. Concordance of the TRUGENE
assay with NS3/4A or NS5B assays was lower than LiPA v2, but still
remained high (79.6%). These ﬁndings are consistent with previous
reports where the LiPA v2 assay was a more accurate method of
determining HCV genotype subtype than the TRUGENE assay
(Germer et al., 2003; Stelzl et al., 2007; Hedskog et al., 2014).
Among our samples that could not be subtyped with TRUGENE,
43.8% were G1a and 55.8% were G1b; this ratio was similar to
the overall results (35.9% and 63.5%) indicating no apparent error
bias for a speciﬁc subtype. This study also showed that there is a
very low risk of erroneously subtyping a HCV G1a with Q80K as
G1b with either assay. Of HCV G1a (determined by NS3/4A or
NS5B sequence based assay) patients with Q80K, 1.3% (3/237)
and 0% (0/237) were erroneously subtyped as G1b by the LiPA v2
and TRUGENE assays, respectively.5. Conclusions
Overall, there was a low prevalence of the Q80K polymorphism
in HCV patients infected with HCV G1 living in the European
region. However, Q80K prevalence varied between countries due
to different Q80K prevalence within the HCV G1 populations and
differing ratios with G1a compared with G1b.Grant support
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Glossary
Q80K is a naturally occurring amino acid substitution occurring
in the NS3 protease domain. This NS3 polymorphism is mainly
present in HCV G1a, conferring low level resistance to in vitro sim-
eprevir activity.
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